Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: weight

Seq & Ye Shall Find

Philip Seo, MD, MHS  |  January 16, 2020

I nodded, gravely. I was recently privileged to attend a symposium on eosinophils. I realize that this sounds odd. And it was odd, mainly because I’m not an eosinophil expert. Still, they were in need of someone who knew something about eosinophilic granulomatosis with polyangiitis, so I managed to sneak in through the back door….

Filed under:OpinionResearch RheumRheuminationsSpeak Out Rheum Tagged with:Eosinophilianext generation sequencingResearch

Tears of Knee Ligaments & Meniscus Carry Highest Arthritis Risk

Lisa Rapaport  |  January 6, 2020

(Reuters Health)—Young adults who have had knee injuries are much more likely than uninjured peers to develop knee osteoarthritis (OA) by middle age, especially if they have broken bones or torn connective tissue, a recent study suggests. Cruciate ligament injuries were associated with a 19.6% greater risk of knee osteoarthritis, the study found. Meniscal tears…

Filed under:ConditionsOsteoarthritis and Bone Disorders

New ACR/EULAR IgG4 Classification Criteria Introduced

Arthritis & Rheumatology  |  January 2, 2020

Immunoglobulin G4-related disease (IgG4-RD) can cause fibroinflammatory lesions in nearly any organ. Correlation among clinical, serologic, radiologic and pathologic data is required for diagnosis. ACR/EULAR classification criteria for IgG4-RD have now been developed and validated in a large cohort of patients…

Filed under:ConditionsOther Rheumatic ConditionsResearch Rheum Tagged with:Arthritis & RheumatologyIgG4-RDResearch

Hair dye being applied to a man’s beard.

Case Report: A 50-Year-Old Man Suffers Dye-Induced Arthritis

Hrudya Abraham, MD, Eric Warm, MD, FACP, & Avis Ware, MD  |  December 18, 2019

Hair dye products are commonly used by both men and women to enhance youth and beauty and to follow fashion trends. As reported in the medical literature, hair dyes and their ingredients are associated with allergic contact dermatitis. A possible association with joint inflammation has also been recognized. There is literature to support that para-phenylenediamine…

Filed under:Conditions Tagged with:case reportenvironmental factorpara-phenylenediamine (PPD)

FDA Approves Nintedanib for SSc-ILD, But Temper Your Expectations

Michael Putman, MD  |  December 18, 2019

The U.S. Food & Drug Admin­istration (FDA) approved nintedanib for systemic sclerosis associated interstitial lung disease (SSc-ILD) on Sept. 6 after a randomized, controlled trial (SENSCIS) demonstrated significant benefit against placebo.1 At a cost of $96,000 per year, treatment reduced the adjusted annual rate of change in forced vital capacity (FVC) from –93.3 mL in…

Filed under:ConditionsDrug UpdatesSystemic Sclerosis Tagged with:interstitial lung disease (ILD)nintedanibSSc-ILDsystemic sclerosis (SSc)

Remote Use of the Multidimensional Health Assessment Questionnaire (MDHAQ)

Juan Schmukler, MD, & Theodore Pincus, MD  |  December 18, 2019

The patient medical history is far more prominent in clinical decisions for rheumatology than for many common chronic diseases in which a gold standard biomarker, such as blood pressure or serum glucose, is applicable to diagnosis and management of all individual patients.1 Components of a subjective patient history may be recorded as structured, quantitative, standard,…

Filed under:ConditionsTechnology Tagged with:case reportMultidimensional Health Assessment Questionnaire (MDHAQ)Routine Assessment of Patient Index Data (RAPID)

Beyond Drugs: ACR/AF Guideline Update for Hand, Knee & Hip OA Emphasizes Exercise

Susan Bernstein  |  December 12, 2019

Guideline authors discussed therapeutic options for patients with hand, knee and hip OA in a session at the 2019 ACR/ARP Annual Meeting.

Filed under:Clinical Criteria/GuidelinesConditionsMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:2019 ACR/ARP Annual Meetinghand osteoarthritiship osteoarthritsknee osteoarthritisosteoarthritis (OA)

Tildrakizumab Promising for Psoriasis in Patients with PsA

Michele B. Kaufman, PharmD, BCGP  |  December 2, 2019

New research shows tildrakizumab may significantly improve psoriasis in patients with active psoriatic arthritis…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:2019 ACR/ARP Annual MeetingPsoriasisPsoriatic Arthritistildrakizumab

New Draft Gout Guideline Released

Susan Bernstein  |  November 20, 2019

ATLANTA—The authors of the new draft ACR treatment guideline for the management of gout presented the draft guideline on Nov. 13 at the 2019 ACR/ARP Annual Meeting. Based on evidence from more than 130 published studies, there are 42 recommendations, of which 16 were strong, including 27 for urate-lowering therapy (ULT) management, 13 of which…

Filed under:Clinical Criteria/GuidelinesConditionsGout and Crystalline Arthritis Tagged with:2019 ACR/ARP Annual MeetingGout

Case Report: Rheumatoid Arthritis-Associated Restrictive Pericarditis

Scott Rodriguez, MD, Kenton Powell, MD, & Daniel Albert, MD  |  November 17, 2019

Rheumatoid arthritis (RA) is a systemic autoimmune disease that affects approximately 1% of the adult population, and involvement of extra-articular tissue occurs in approximately 40% of patients over their lifetimes.1 RA-associated pericardial disease is an uncommon complication, and surgery is the only definitive therapy—according to current literature. In this report, we present the case of…

Filed under:ConditionsRheumatoid Arthritis Tagged with:anti-CD20 therapyPericarditisrituximab

  • « Previous Page
  • 1
  • …
  • 26
  • 27
  • 28
  • 29
  • 30
  • …
  • 93
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences